We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.735 | 1.54% | 48.565 | 48.56 | 48.58 | 48.84 | 48.11 | 48.14 | 1,026,918 | 19:08:56 |
From May 2019 to May 2024
By Matt Grossman
Sanofi's Sarclisa, an immunotherapy for patients with multiple myeloma, has been approved by Canada's health authority, Sanofi said Wednesday.
The treatment was approved to treat patients who have had at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa was approved to be used in conjunction with pomalidomide and dexamethasone.
The drug's approval was based on a study that showed statistically significant improvement in patients' progression-free survival, Sanofi said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 08, 2020 07:50 ET (11:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
